Reviewing ALSFRS-R as the Established Endpoint for ALS Clinical Trials

Time: 1:45 pm
day: Day Two AM


  • Demonstrating and quantifying challenges with the ALSFRS-R endpoint in its current state
  • Showcasing evidence from alternative measurements to demonstrate impact on disease progression
  • Outlining ongoing strategy to approach regulatory review through leveraging regulatory flexibility